Calliditas Therapeutics AB-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Calliditas Therapeutics AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011796
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Calliditas Therapeutics AB (Calliditas), formerly, Pharmalink AB is a pharmaceutical company that identifies, develops and commercializes pharmaceutical products for niche indications. The company’s product pipeline includes Nefecon for IgA Nephritis that is under Phase II clinical trials; and Busulipo which is under Phase II clinical trials. Its pipeline product also includes Xepol XP-28, which is used for the treatment of post-polio syndrome and is under pre-license sales.Calliditas also partners with medical research institutions including the Karolinska Institute and Uppsala University. Calliditas is headquartered in Stockholm, Sweden.

Calliditas Therapeutics AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Calliditas Therapeutics AB, Medical Devices Deals, 2011 to YTD 2017 9
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Pharmalink Acquires Anti-Inflammatory Drug from Synartro 11
Venture Financing 12
Pharmalink Raises USD12 Million in Financing 12
Pharmalink Raises US$15 Million In Series C Financing 13
Pharmalink Secures US$5.1 Million In Series B Financing 15
Partnerships 16
Archimedes Pharma Enters Into Licensing Agreement With Pharmalink 16
Equity Offering 17
Pharmalink Plans IPO 17
Calliditas Therapeutics AB – Key Competitors 18
Calliditas Therapeutics AB – Key Employees 19
Calliditas Therapeutics AB – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Corporate Communications 21
Aug 24, 2017: Thomas Eklund New Chairman of Pharmalink 21
Aug 15, 2017: Pharmalink strengthens its management team. Appoints new Chief Financial Officer and head of communications 22
Jan 09, 2017: Pharmalink strengthens board with appointment of Maria Carell as Chair 23
Nov 30, 2016: Sweden’s Pharmalink obtains OMP designation for Nefecon 24
Other Significant Developments 25
Nov 15, 2017: Pharmalink is renamed Calliditas Therapeutics 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Key Facts 2
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Calliditas Therapeutics AB, Deals By Therapy Area, 2011 to YTD 2017 8
Calliditas Therapeutics AB, Medical Devices Deals, 2011 to YTD 2017 9
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Pharmalink Acquires Anti-Inflammatory Drug from Synartro 11
Pharmalink Raises USD12 Million in Financing 12
Pharmalink Raises US$15 Million In Series C Financing 13
Pharmalink Secures US$5.1 Million In Series B Financing 15
Archimedes Pharma Enters Into Licensing Agreement With Pharmalink 16
Pharmalink Plans IPO 17
Calliditas Therapeutics AB, Key Competitors 18
Calliditas Therapeutics AB, Key Employees 19

★海外企業調査レポート[Calliditas Therapeutics AB-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Shiseido Co Ltd (4911):企業の財務・戦略的SWOT分析
    Shiseido Co Ltd (4911) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • APR Applied Pharma Research SA-製薬・医療分野:企業M&A・提携分析
    Summary APR Applied Pharma Research SA (APR) is a healthcare company which focuses on the development and licenses of healthcare products for rare therapeutic areas. The company offers consumer health products, prescription healthcare products and therapeutic products. APR’s product pipeline portfol …
  • Axelar AB-製薬・医療分野:企業M&A・提携分析
    Summary Axelar AB (Axelar) is a drug development company that develops various novel anti-cancer treatments. The company develops AXL1717, a novel anti cancer compound that inhibits tumor growth and reduces tumor sizes of malignant cells such as prostate cancer, breast cancer, glioblastoma, sarcoma, …
  • Banyan Tree Holdings Ltd:企業の戦略・SWOT・財務情報
    Banyan Tree Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Banyan Tree Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Zain Group (ZAIN):企業の財務・戦略的SWOT分析
    Zain Group (ZAIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Exelon Corporation:企業のM&A・事業提携・投資動向
    Exelon Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Exelon Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Admedus Ltd (AHZ):企業の財務・戦略的SWOT分析
    Admedus Ltd (AHZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Sempra Energy (SRE):企業の財務・戦略的SWOT分析
    Sempra Energy (SRE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Maersk Line AS:企業の戦略的SWOT分析
    Maersk Line AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Capsugel Inc-製薬・医療分野:企業M&A・提携分析
    Summary Capsugel Inc (Capsugel) is a contract manufacturing company which designs, develops and manufactures a range of innovative dosage forms. It provides contract services to the biopharmaceutical and consumer health and nutrition industries. The company’s services enable clients to enhance the b …
  • Ringkjoebing Landbobank A/S:企業の戦略・SWOT・財務情報
    Ringkjoebing Landbobank A/S - Strategy, SWOT and Corporate Finance Report Summary Ringkjoebing Landbobank A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Cipla Ltd (CIPLA):医療機器:M&Aディール及び事業提携情報
    Summary Cipla Ltd (Cipla) is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products for the treatment of various conditions such as cardiovascular and pediatric diseases, dermatological and cosmetologi …
  • Mitralign Inc:医療機器:M&Aディール及び事業提携情報
    Summary Mitralign Inc (Mitralign) is a medical device company that offers direct transcatheter annuloplasty system to treat both functional tricuspid regurgitation and mitral regurgitation. The company’s products include crossing wire, pledget delivery catheter and placation lock delivery catheter, …
  • Baker Botts LLP:企業の戦略的SWOT分析
    Baker Botts LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Bafna Pharmaceuticals Ltd (BAFNAPHARM)-製薬・医療分野:企業M&A・提携分析
    Summary Bafna Pharmaceuticals Ltd (Bafna Pharmaceuticals) is a pharmaceutical company which manufactures and markets pharmaceutical products. The company’s operations include domestic marketing, international marketing, international export and business development. Its products comprise raricap, ra …
  • Ashok Leyland Ltd (ASHOKLEY):企業の財務・戦略的SWOT分析
    Ashok Leyland Ltd (ASHOKLEY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Proxy Biomedical Ltd-医療機器分野:企業M&A・提携分析
    Summary Proxy Biomedical Ltd (PBL) is a medical device company that research, develops and manufactures biomaterials for medical implant products. The company’s products include composite mesh, flat sheet 2D and 3D mesh, hernia plugs, resorbable synthetic mesh, resorbable surgical mesh, specialty su …
  • Golden Dawn Minerals Inc (GOM):企業の財務・戦略的SWOT分析
    Summary Golden Dawn Minerals Inc (Golden Dawn) is a mining and mineral exploration and development company. it offers acquisition, exploration, operations, management, production, and development of gold, uranium, silver, iron, lead, zinc, base metals, precious metals, and mineral resource deposit p …
  • Acuity Brands Inc (AYI)-エネルギー分野:企業M&A・提携分析
    Summary Acuity Brands, Inc. (Acuity Brands) provides lighting and building management solutions and services. The company offers lighting solutions including devices such as luminaires, lighting controls, lighting components, power supplies, prismatic skylights, and integrated lighting systems. It a …
  • Takara Bio Inc (4974):企業の財務・戦略的SWOT分析
    Summary Takara Bio Inc (Takara), a subsidiary of Takara Holdings Inc, is a biotechnology company that develops, manufactures and distributes biotechnology research reagents and equipments for life sciences research. The company sells gene amplification system and offers scientific instruments. It of …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆